These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

893 related items for PubMed ID: 34372900

  • 1. The impact of COVID-19 on healthcare delivery for people who use opioids: a scoping review.
    Alexander K, Pogorzelska-Maziarz M, Gerolamo A, Hassen N, Kelly EL, Rising KL.
    Subst Abuse Treat Prev Policy; 2021 Aug 09; 16(1):60. PubMed ID: 34372900
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.
    Dadiomov D, Bolshakova M, Mikhaeilyan M, Trotzky-Sirr R.
    Harm Reduct J; 2022 Jun 29; 19(1):69. PubMed ID: 35768817
    [Abstract] [Full Text] [Related]

  • 6. An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic.
    Hughes PM, Verrastro G, Fusco CW, Wilson CG, Ostrach B.
    J Rural Health; 2021 Jun 29; 37(3):467-472. PubMed ID: 33720447
    [Abstract] [Full Text] [Related]

  • 7. COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management.
    Mehtani NJ, Ristau JT, Snyder H, Surlyn C, Eveland J, Smith-Bernardin S, Knight KR.
    Subst Abus; 2021 Jun 29; 42(2):205-212. PubMed ID: 33684331
    [Abstract] [Full Text] [Related]

  • 8. Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic.
    Peckham AM, Ball J, Colvard MD, Dadiomov D, Hill LG, Nichols SD, Tallian K, Ventricelli DJ, Tran TH.
    Am J Health Syst Pharm; 2021 Mar 18; 78(7):613-618. PubMed ID: 33411894
    [Abstract] [Full Text] [Related]

  • 9. Predictors of opioid overdose during the COVID-19 pandemic: The role of relapse, treatment access and nonprescribed buprenorphine/naloxone.
    Kline A, Williams JM, Steinberg ML, Mattern D, Chesin M, Borys S, Chaguturu V.
    J Subst Use Addict Treat; 2023 Jun 18; 149():209028. PubMed ID: 37003539
    [Abstract] [Full Text] [Related]

  • 10. Opioid Use Disorder and COVID-19: Crashing of the Crises.
    Khatri UG, Perrone J.
    J Addict Med; 2020 Jun 18; 14(4):e6-e7. PubMed ID: 32404651
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The intertwined expansion of telehealth and buprenorphine access from a prescriber hub.
    Moore DT, Wischik DL, Lazar CM, Vassallo GG, Rosen MI.
    Prev Med; 2021 Nov 18; 152(Pt 2):106603. PubMed ID: 33974959
    [Abstract] [Full Text] [Related]

  • 14. Using telehealth to improve buprenorphine access during and after COVID-19: A rapid response initiative in Rhode Island.
    Clark SA, Davis C, Wightman RS, Wunsch C, Keeler LAJ, Reddy N, Samuels EA.
    J Subst Abuse Treat; 2021 May 18; 124():108283. PubMed ID: 33771282
    [Abstract] [Full Text] [Related]

  • 15. Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone.
    Kelty E, Hulse G.
    Int J Drug Policy; 2017 Aug 18; 46():54-60. PubMed ID: 28609749
    [Abstract] [Full Text] [Related]

  • 16. Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic.
    Currie JM, Schnell MK, Schwandt H, Zhang J.
    JAMA Netw Open; 2021 Apr 01; 4(4):e216147. PubMed ID: 33856474
    [Abstract] [Full Text] [Related]

  • 17. "No home to take methadone to": Experiences with addiction services during the COVID-19 pandemic among survivors of opioid overdose in Boston.
    Harris MTH, Lambert AM, Maschke AD, Bagley SM, Walley AY, Gunn CM.
    J Subst Abuse Treat; 2022 Apr 01; 135():108655. PubMed ID: 34772604
    [Abstract] [Full Text] [Related]

  • 18. Designing and Evaluating COVID-19 Protocols for an Office-Based Opioid Treatment Program in an Urban Underserved Setting.
    O'Gurek DT.
    J Am Board Fam Med; 2021 Feb 01; 34(Suppl):S136-S140. PubMed ID: 33622828
    [Abstract] [Full Text] [Related]

  • 19. Opioid treatment programs, telemedicine and COVID-19: A scoping review.
    Chan B, Bougatsos C, Priest KC, McCarty D, Grusing S, Chou R.
    Subst Abus; 2022 Feb 01; 43(1):539-546. PubMed ID: 34520702
    [Abstract] [Full Text] [Related]

  • 20. Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study.
    Robbins M, Haroz R, Mazzarelli A, Clements D, Jones CW, Salzman M.
    J Subst Abuse Treat; 2021 Nov 01; 130():108405. PubMed ID: 34118697
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.